Lion Biotechnologies (IOVA) Receives Daily News Sentiment Rating of 0.25
News headlines about Lion Biotechnologies (NASDAQ:IOVA) have been trending somewhat positive on Monday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lion Biotechnologies earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.7414403630279 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Nittany Lions cruise past Georgia State (dailyitem.com)
- Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer (finance.yahoo.com)
- Lion Biotechnologies’ (IOVA) “Buy” Rating Reaffirmed at Chardan Capital (americanbankingnews.com)
- Lion Biotechnologies, Inc. (IOVA) Earns “Buy” Rating from HC Wainwright (americanbankingnews.com)
- Lion Biotechnologies, Inc. (IOVA) Given a $13.00 Price Target at Oppenheimer Holdings, Inc. (americanbankingnews.com)
Several research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Lion Biotechnologies in a research note on Wednesday, September 13th. Chardan Capital reissued a “buy” rating on shares of Lion Biotechnologies in a research note on Thursday, September 7th. Oppenheimer Holdings, Inc. set a $13.00 price objective on shares of Lion Biotechnologies and gave the company a “buy” rating in a research note on Monday, September 11th. Jefferies Group LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Lion Biotechnologies in a research note on Tuesday, September 5th. Finally, Cowen and Company reissued a “buy” rating on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $13.88.
Lion Biotechnologies (NASDAQ:IOVA) traded up 5.73% on Monday, hitting $8.30. 439,847 shares of the stock traded hands. The firm’s 50-day moving average price is $5.61 and its 200-day moving average price is $6.42. Lion Biotechnologies has a 12-month low of $4.45 and a 12-month high of $8.61. The stock’s market cap is $520.30 million.
About Lion Biotechnologies
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Stock Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related stocks with our FREE daily email newsletter.